Aptose Biosciences Inc. (APTO)
NASDAQ: APTO · Real-Time Price · USD
0.208
-0.009 (-4.27%)
Jan 22, 2025, 2:00 PM EST - Market open
Aptose Biosciences Employees
As of December 31, 2023, Aptose Biosciences had 36 total employees, including 35 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
36
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$994,444
Market Cap
13.07M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
APTO News
- 12 days ago - Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial - GlobeNewsWire
- 4 weeks ago - Aptose Announces Positive Decision by Nasdaq Hearings Panel - GlobeNewsWire
- 5 weeks ago - Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax - GlobeNewsWire
- 6 weeks ago - Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML - GlobeNewsWire
- 7 weeks ago - Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials - GlobeNewsWire
- 2 months ago - Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering - GlobeNewsWire
- 2 months ago - Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering - GlobeNewsWire
- 2 months ago - Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy - GlobeNewsWire